Description
CS-7017 monohydrate is a peroxisome proliferator activated receptor gamma (PPAR) agonist. It is a potential therapy for thyroid cancer and liposarcoma. It is also used for the treatment of rectal cancer and non-small cell lung cancer. It was developed by Daiichi Sankyo Company Limited. It is in clinic phase 2 with no progress